Anne Johnson
Director of Finance/CFO chez ATAI LIFE SCIENCES N.V.
Fortune : 144 972 $ au 31/03/2024
Profil
Anne Johnson is currently the Chief Financial & Accounting Officer at ATAI Life Sciences NV.
She previously worked as the Corporate Controller at Chimerix, Inc., Vice President-Finance at Xanodyne Pharmaceuticals, Inc., and Controller at Aruvant Sciences, Inc. Ms. Johnson completed her undergraduate degree at The University of North Carolina at Wilmington.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ATAI LIFE SCIENCES N.V.
0,04% | 02/04/2024 | 73 590 ( 0,04% ) | 144 972 $ | 31/03/2024 |
Postes actifs de Anne Johnson
| Sociétés | Poste | Début |
|---|---|---|
| ATAI LIFE SCIENCES N.V. | Director of Finance/CFO | 13/10/2023 |
Anciens postes connus de Anne Johnson
| Sociétés | Poste | Fin |
|---|---|---|
| CHIMERIX, INC. | Comptroller/Controller/Auditor | - |
Xanodyne Pharmaceuticals, Inc.
 Xanodyne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY. | Director of Finance/CFO | - |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Comptroller/Controller/Auditor | - |
Formation de Anne Johnson
| The University of North Carolina at Wilmington | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| ATAI LIFE SCIENCES N.V. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Xanodyne Pharmaceuticals, Inc.
Xanodyne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY. | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
